Technical Analysis for MGTX - MeiraGTx Holdings plc

Grade Last Price % Change Price Change
grade A 23.48 1.78% 0.41
MGTX closed up 1.78 percent on Friday, May 17, 2019, on 74 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical MGTX trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Spinning Top Other 0.00%
Calm After Storm Range Contraction 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%

Older signals for MGTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.
Technology California Gene Therapy Macular Degeneration Gene Delivery Adeno Associated Virus AAV Advanced Micro Devices Pipeline Products
Is MGTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 17 Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
May 17 The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
May 14 Microcaps mostly among midday movers
May 14 MeiraGTx gene therapy shows positive action in early-stage study in inherited eye disorder
May 14 MeiraGTx beats by $0.02
May 14 MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 14 MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
May 10 MeiraGTx Appoints Nicole Seligman to Board of Directors
May 6 MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference
Apr 25 MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019
See more MGTX news...
Indicators
Indicator Value
52 Week High 24.11
52 Week Low 7.98
Average Volume 142,855
200-Day Moving Average 13.817
50-Day Moving Average 19.1438
20-Day Moving Average 19.2975
10-Day Moving Average 20.024
Average True Range 1.4236
ADX 22.14
+DI 29.942
-DI 11.4109
Chandelier Exit (Long, 3 ATRs ) 19.8392
Chandelier Exit (Short, 3 ATRs ) 21.7708
Upper Bollinger Band 22.7571
Lower Bollinger Band 15.8379
Percent B (%b) 1.1
BandWidth 35.855422
MACD Line 0.9393
MACD Signal Line 0.4121
MACD Histogram 0.5272
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.44
Resistance 3 (R3) 26.32 25.21 25.94
Resistance 2 (R2) 25.21 24.46 25.27 25.78
Resistance 1 (R1) 24.35 24.00 24.78 24.47 25.61
Pivot Point 23.24 23.24 23.46 23.30 23.24
Support 1 (S1) 22.38 22.49 22.81 22.50 21.35
Support 2 (S2) 21.27 22.03 21.33 21.18
Support 3 (S3) 20.41 21.27 21.02
Support 4 (S4) 20.53